文献速递肝病

低至中等量饮酒与代谢功能障碍相关脂肪性肝病个体纤维化增加相关

Low-to-moderate alcohol consumption is associated with increased fibrosis in individuals with metabolic dysfunction-associated steatotic liver disease.
PubMed 文献 · J Hepatol · 2024-07-04

该研究基于西班牙(衍生队列)和美国(验证队列)的人群瞬时弹性成像数据,评估不同饮酒水平对脂肪性肝病严重程度的影响及其与代谢合并症的交互作用。结果显示,中等量饮酒在MASLD中常见,并使进展期疾病风险升高至与MetALD相似的水平;在MASLD患者中,中等量饮酒与代谢危险因素呈超相加效应,指数级增加肝纤维化风险。

要点

  • 中等量饮酒在MASLD中常见,并增加进展期疾病风险至与MetALD相似水平。
  • 饮酒量与代谢因素数量之间呈剂量依赖性增加显著纤维化和高危MASH的患病率。
  • 验证队列中,中等量饮酒与有进展风险的MASLD相关(OR 1.69,95%CI 1.06-2.71)。

核心结论

  • 中等量饮酒在MASLD中常见,并使进展期疾病风险升高至与MetALD相似的水平。
  • 中等量饮酒与代谢危险因素呈超相加效应,指数级增加肝纤维化风险。
  • 这些结果提示,在代谢状态不健康和MASLD患者中,每日饮酒没有安全限量。

研究设计与样本

  • 基于西班牙(衍生队列)和美国(验证队列)参与者瞬时弹性成像(FibroScan®)数据的人群研究。
  • 衍生队列纳入2,227例MASLD个体(9%报告低饮酒量,14%报告中等饮酒量)和76例MetALD。
  • 验证队列纳入1,732例MASLD参与者。

主要发现

  • 衍生队列中,显著纤维化和高危MASH的总体患病率分别为7.6%和14.8%。
  • 多变量分析中,饮酒与显著纤维化和高危MASH独立相关。
  • 饮酒杯数/周与心血管代谢因素数量之间观察到显著纤维化和高危MASH患病率的剂量依赖性增加。
  • 验证队列中,17%有显著纤维化,13%有高危MASH;该队列验证了中等量饮酒与有进展风险的MASLD之间的关联(OR 1.69,95%CI 1.06-2.71)。

关键数值与推荐

  • SLD定义为受控衰减参数≥275 dB/m。
  • MASLD需至少存在一项心血管代谢危险因素。
  • MASLD患者中,低饮酒量定义为平均5-9杯/周;中等量饮酒定义为女性10-13杯/周、男性10-20杯/周;饮酒量增加(MetALD)定义为女性14-35杯/周、男性21-42杯/周。
  • 显著纤维化定义为肝硬度测量≥8 kPa;高危MASH定义为FAST评分≥0.35。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: Both metabolic dysfunction and alcohol consumption cause steatotic liver disease (SLD). The distinction between metabolic dysfunction-associated SLD (MASLD) and MetALD categories is based on arbitrary thresholds of alcohol intake. Thus, we assessed the impact of different levels of alcohol consumption on SLD severity and their interaction with metabolic comorbidities. METHODS: We performed a population-based study with transient elastography (FibroScan®) data from participants in Spain (derivation cohort) and the US (validation cohort). A controlled attenuation parameter ≥275 dB/m was used to define SLD. At least one cardiometabolic risk factor was required to define MASLD. Among patients with MASLD, low alcohol consumption was defined as an average of 5-9 drinks/week, moderate consumption as 10-13 drinks/week for females and 10-20 drinks/week for males, and increased alcohol intake (MetALD) as 14-35 drinks/week for females and 21-42 drinks/week for males. Significant fibrosis was defined as a liver stiffness measurement ≥8 kPa and at-risk metabolic dysfunction-associated steatohepatitis (MASH) as a FAST score ≥0.35. RESULTS: The derivation cohort included 2,227 individuals with MASLD (9% reported low, 14% moderate alcohol consumption) and 76 cases with MetALD. Overall prevalences of significant fibrosis and at-risk MASH were 7.6% and 14.8%, respectively. In the multivariable analysis, alcohol consumption was independently associated with significant fibrosis and at-risk MASH. A dose-dependent increase in the prevalence of significant fibrosis and at-risk MASH was observed between the number of drinks/week and the number of cardiometabolic factors. The validation cohort included 1,732 participants with MASLD, of whom 17% had significant fibrosis and 13% at-risk MASH. This cohort validated the association between moderate intake and MASLD at risk of progression (odds ratio 1.69, 95% CI 1.06-2.71). CONCLUSIONS: Moderate alcohol intake is commonly seen in MASLD and increases the risk of advanced disease to a level similar to that observed in MetALD. IMPACT AND IMPLICATIONS: Metabolic risk factors such as overweight, diabetes or dyslipidemia, and alcohol consumption can cause liver disease. These factors frequently coexist, but their joint effects on liver fibrosis remain uncertain. In this study, we have analyzed individuals from the general population with MASLD (metabolic dysfunction-associated steatotic liver disease) enrolled in Spain and the US. We show that moderate alcohol consumption has a supra-additive effect with metabolic risk factors, exponentially increasing the risk of liver fibrosis. These results suggest that there are no safe limits of daily alcohol intake in patients with unhealthy metabolic status and MASLD.

来源:J Hepatol,查看原文。版权归原作者所有。

引用

  1. Marti-Aguado D, Calleja JL, Vilar-Gomez E, et al. Low-to-moderate alcohol consumption is associated with increased fibrosis in individuals with metabolic dysfunction-associated steatotic liver disease. J Hepatol. 2024. PMID: 38971533. doi:10.1016/j.jhep.2024.06.036

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。